| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Other current assets | 4,035 | |||
| Inventories | 9,719 | |||
| Cash and cash equivalents | 62,293 | |||
| Accounts receivable, net | 15,740 | |||
| Total current assets | 91,787 | |||
| Property and equipment, net | 269 | |||
| Other assets | 646 | |||
| Operating lease right-of-use assets | 3,109 | |||
| Inventories, long-term | 19,223 | |||
| Intangible assets, net | 2,177 | |||
| Total assets | 117,211 | |||
| Accrued liabilities | 14,888 | |||
| Operating lease liabilities, current portion | 486 | |||
| Accounts payable | 7,571 | |||
| Total current liabilities | 22,945 | |||
| Accrued milestones | 3,200 | |||
| Other liabilities | 935 | |||
| Operating lease liabilities, long-term portion | 2,638 | |||
| Total liabilities | 29,718 | |||
| Accumulated deficit | -495,571 | |||
| Common stock, 0.0001 par value, 100,000,000 shares authorized at june 30, 2025 and december 31, 2024 45,438,420 and 44,988,313 shares issued and outstanding at june 30, 2025 and december 31, 2024, respectively | 5 | |||
| Additional paid-in capital | 583,671 | |||
| Accumulated other comprehensive income | -612 | |||
| Total stockholders' equity | 87,493 | |||
| Total liabilities and stockholders' equity | 117,211 | |||
Y-mAbs Therapeutics, Inc. (YMAB)
Y-mAbs Therapeutics, Inc. (YMAB)